Blueprint Medicines Corporation BPMC
Trading inactive
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Michael Schmidt | Guggenheim | 127.6 $ | 132 $ | 4.40 % | 03/06/2025 |
| Ami Fadia | Needham | 89.24 $ | 135 $ | 45.76 % | 31/10/2024 |
| David Dai | UBS | 84.4 $ | 88 $ | 3.60 % | 24/10/2024 |
| Bradley Canino | Stifel Nicolaus | 90.94 $ | 155 $ | 64.06 % | 19/09/2024 |
| Matthew Biegler | Oppenheimer | 102.045 $ | 130 $ | 27.96 % | 01/08/2024 |
| Peter Lawson | Barclays | 112.19 $ | 105 $ | -7.19 % | 29/07/2024 |
| Matthew Biegler | Oppenheimer | 116.55 $ | 125 $ | 8.45 % | 08/07/2024 |
| Andrew Berens | Leerink Partners | 107.19 $ | 97 $ | -10.19 % | 06/05/2024 |
| Christopher Raymond | Raymond James | 106.285 $ | 104 $ | -2.29 % | 03/05/2024 |
| Andrew Fein | H.C. Wainwright | 107 $ | 135 $ | 28.00 % | 03/05/2024 |
| Andrew Fein | H.C. Wainwright | 46.1 $ | 70 $ | 23.90 % | 02/11/2022 |
| Matthew Biegler | Oppenheimer | 70.66 $ | 90 $ | 19.34 % | 06/09/2022 |
| Derek Archila | Wells Fargo | 52.775 $ | 41 $ | -11.78 % | 17/08/2022 |
| Christopher Raymond | Piper Sandler | 55.5 $ | 65 $ | 9.50 % | 18/05/2022 |
| Michael Ulz | Morgan Stanley | 79.16 $ | 92 $ | 12.84 % | 01/02/2022 |
| Michael Schmidt | Guggenheim | 110.08 $ | 122 $ | 11.92 % | 03/01/2022 |
| Dane Leone | Raymond James | 114.95 $ | 133 $ | 18.05 % | 09/11/2021 |
| Salveen Richter | Goldman Sachs | 84.74 $ | 147 $ | 62.26 % | 29/07/2021 |
| Arlinda Lee | Canaccord Genuity | 83.53 $ | 120 $ | 36.47 % | 17/06/2021 |